Pharmacological treatment of cognitive deficits in nondementing mental health disorders

Trevor W. Robbins, PhD

Evidence for pharmacological remediation of cognitive deficits in three major psychiatric disorders—attention deficit-hyperactivity disorder (ADHD), schizophrenia, and depression—is reviewed. ADHD is effectively treated with the stimulant medications methylphenidate and d-amphetamine, as well as nonstimulants such as atomoxetine, implicating cognitive enhancing effects mediated by noradrenaline and dopamine. However, the precise mechanism underlying these effects remains unclear. Cognitive deficits in schizophrenia are less effectively treated, but attempts via a variety of neurotransmitter strategies are surveyed. The possibility of treating cognitive deficits in depression via antidepressant medication (e.g., selective serotonin reuptake inhibitors) and by adjunctive drug treatment has only recently received attention because of confounding, or possibly interactive, effects on mood. Prospects for future advances in this important area may need to take into account transdiagnostic perspectives on cognition (including neurodegenerative diseases) as well as promising insights in neuropsychological, neurobiological, and clinical trial design approaches to cognitive enhancement.

Keywords: cognition; memory; attention; ADHD; schizophrenia; depression; dopamine; noradrenaline; serotonin; glutamate; GABA

Introduction

This important topic can be considered with either a narrow or broad focus. If, for example, the position is taken that most psychiatric symptoms can be understood as impairments of cognition, or of cognition interacting with emotional or motivational factors (i.e., so-called “hot” cognition), then we would be discussing the whole remit of pharmacological treatment in psychiatry. If on the other hand, we consider specifically the deficits in “cold” cognition, for example, memory and attention, that accompany such diagnoses as schizophrenia and depression and most other neuropsychiatric disorders, then we are dealing with a narrower spectrum. Whilst it is now acknowledged that cognitive dysfunctions play a major role in mental health disorders, and that describing these and their neural basis, and identifying possible pharmacological treatments for them, have been important research objectives, it must also be admitted that there have been rather few clinical successes to date.

The search for new cognitive treatments may be aided by recognizing apparently similar cognitive dysfunctions in what otherwise appear to be very different neuropsychiatric phenotypes. In other words, a memory or attentional deficit in schizophrenia could possibly be treated with a similar medication as in attention deficit-hyperactivity disorder (ADHD). This strategy accepts that the enormous capacity for comorbidity in psychiatry may also extend to the cognitive dimensions. Such considerations mean that the treatment of cognitive impairments associated with neuro-

Author affiliations: Departm ent of Psychology and Behavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge, UK. Address for correspondence: Dept of Psychology, Downing St, Cambridge CB2 3EB, UK. (email: twr2@cam.ac.uk)
Degenerative diseases that are not generally considered as "mental health disorders" may also be degenerative. Neurodegenerative disorders such as Alzheimer disease, Lewy body disease, and frontotemporal dementia also have deficits in major, although somewhat distinct, areas of cognition, as their defining characteristics. Although they are not usually defined as mental health disorders, Parkinson disease and Huntington disease, although classically categorized as movement disorders, course show clinically significant impairments in the domains of affect and cognition. It can hardly be claimed that pharmacological treatments of cognitive disorders in these conditions have yet been crowned with success, but this experience may also prove to be informative. In this review, I will focus initially on the status of well-established pharmacological treatments for cognitive impairments in ADHD before considering the present, less clear, status of treatments for cognitive deficits in schizophrenia and depression. I will also consider some future prospects for treating cognition with pharmacological agents in these disorders. Table 1 provides a “roadmap” for this brief survey, indicating the main drugs used for treating cognition in these three psychiatric disorders (only a few of which are licensed), and incidentally illustrating the diversity and wide range of mechanisms of these compounds.

### Attention deficit-hyperactivity disorder
ADHD in either juveniles or adults is generally thought to exemplify so-called “executive” deficits in cognition, which comprise such components as working memory and planning, cognitive control (including inhibitory response control and cognitive flexibility)—although some authors consider that the impairments extend to broader domains such as other aspects of mental activity. Classically, ADHD also presents with major impairments of sustained attention and distractibility, which have been demonstrated to be related to loss of prefrontal gray matter, not only in individuals with ADHD, but also in their first-degree relatives, suggesting a neurobehavioral endophenotype of the disorder. ADHD is generally considered to be one of the few success stories in treatment in psychiatry. The more severe forms of this disorder are generally treated, apparently paradoxically, with stimulant drugs such as methylphenidate or d-amphetamine, which boost catecholamine function (ie, dopamine [DA] and noradrenaline [NA]) partially as a consequence of their blockade of the DA and NA transporters. Other nonstimulant drugs affecting primarily noradrenergic function are also employed; such as atomoxetine and guanfacine. Meta-analyses indicate that the stimulants exert respectable (medium to large) effect sizes on reducing symptom scores.

| ADHD       | SCHIZOPHRENIA           | DEPRESSION    |
|------------|-------------------------|--------------|
| Methylphenidate | D-cycloserine        | Vortioxetine |
| Amphetamine         | AMPA-R agonists       | Modafinil    |
| Atomoxetine        | Memantine             |              |
| Guanfacine         | Donepezil             |              |
| Bupropion          | Alpha7 nicotinic agonists |         |
| Modafinil          | Amphetamine           |              |
|                  | Modafinil             |              |

Table 1. Drugs used in the treatment of cognitive dysfunction in three psychiatric disorders. ADHD, attention deficit-hyperactivity disorder; AMPA-R, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor.
in both juvenile\(^1\) and adult\(^1\) ADHD. Nonstimulants such as atomoxetine, bupropion, and guanfacine are also effective, although with relatively smaller effect sizes. Some analyses suggest that atomoxetine is also m ore effective than m ethylphenidate, perhaps because of its DA-releasing action.\(^5\) A large recent m eta-analysis\(^6\) based on teachers’ and clinicians’ ratings as the main outcome m easures largely confirm ed the earlier results, the m ain recom m endation being to em ploy m ethylphenidate in children with ADHD and atomoxetine in adult ADHD. These impressive effects are mitigated to some extent by tolerability and side effects of these drugs and the (presently largely unsupported) fear of possible stimulant drug-use disorder.

However, there is also some evidence that long-term treatment with stimulants can have a protective effect against the development of psychiatric disorders such as depression, disruptive behavior, or anxiety, and there was less likelihood of repeating the same school grade.\(^7\) Such effects would suggest some extent by tolerability and side effects of these drugs and the (presently largely unsupported) fear of possible stimulant drug-use disorder.

In parallel to these promising effects on behavioral and cognitive outcomes, Nakao et al\(^8\) reported from another m eta-analysis the remarkable result that long-term stimulant medication appeared to be associated with a norm alization of the reduced gray m att le volum e of basal ganglia structures com only found in ADHD - possibly ininating the “developm ental delay” often postulated in this disorder.

These clinical findings on cognition are in general consistent with considerable evidence that these drugs improve perfor-

m ance on laboratory tests of working m em ory, sustained attention, and inhibitory response control (thus am eliorating im pulsivity) in both juveniles and adults with ADHD.\(^12\) On the other hand, it has also been reported that although, for exam ple, decision-m ak ing cognition m ay be rendered less “risky” by m ethylphenidate, the drug m ay also fail to im prove adjustm ent of risk in the face of changing contingencies.\(^13\) This m ak es it clear that the concept of a general “cognitive enhancer” m ay be inappropriate; cognitive benefits m ay also be accom panied by cognitive costs. This consideration is also relevant to the well-known inverted U-shaped function that often determines effects of drugs on cognition—in its simplest form that optimal effects m ay be obtained by intermediate dose. However, it m ay also be the case that different behavioral and cognitive tasks require different doses for optimal effects. Evidence for this com es from studies of the effects of L-Dopa on cognition in Parkinson’s disease; functions such as spatial working m em ory and cognitive flexibility m ay be im proved but at the cost of risky decision m ak ing and im paired reversals.\(^14,15\) For ADHD, Sprague and Sleator\(^16\) showed that a fam ily of inverted U-shaped functions m ay explain why doses producing optimal objectively measured behavioral effects of stimulants m ay not necessarily correspond to teachers’ or parents’ ratings of efficacy.

A major concern is that despite the relatively successful use of anti-ADHD m edications, there is still no definitive understanding of how they produce their cognitive enhancing effects.\(^17\) Although the m olecular actions of stimulant drugs are quite well understood (eg, their actions on the catecholamine iner transporters), it is still not known, for exam ple, which of the two catecholamine inertransporters, DA or NA (or both in combination) is responsible for their therapeutic actions, or where in the brain, for exam ple, in the prefrontal cortex or striatum they m ost effectiv ely operate. Research findings in both experim ental animals and hum ans indicate that both DA and NA m ay play a role in executive functions, such as working m em ory, response inhibition, and different aspects of attention in the case of DA potentially at either prefrontal or striatal DA receptors and for NA especially, though not exclusively, in the prefrontal cortex.\(^18\) However, there are suggestions from some m e predominantly preclinical studies that NA m ay be m ore im plicated in the control of im pulsive behavior\(^8,20\) and selective attention\(^21,22\) whereas DA plays im portant roles in working m em ory and sustained attention.\(^23,24\)
Precisely how these neurotransmitter modulations serve to improve cognitive performance may depend on their ability to enhance information processing by various actions on signal-to-noise processing in the prefrontal cortex. However, it is intriguing to consider the possibilities that these mechanisms may reflect processes of elevated arousal or even reward-related motivational effects; that the cognitive enhancing effects result from interactions between such processes and information processing. Stimulant drugs are widely known to combat fatigue and drowsiness, but the proposal here is that these modulations of arousal can directly affect cognition even in the non-sleep-deprived subject.

These research findings and hypotheses have not in general yet been tested or translated to human patients with ADHD. Another complication is that many of the cognitive benefits observed in ADHD have also been shown in laboratory studies of healthy individuals. This raises an important issue; whether the drugs are acting to restore a neurochemical deficit associated with the disorder, or whether they are simply producing their cognitive enhancing effects by interacting with largely intact systems to compensate for dysfunctioning neural networks, caused for example by gray matter loss or deficits in functional connectivity.

Although stimulant drug medication for ADHD has been a qualified success, there is still considerable interest in the search for superior drugs without the possible stigma of being drugs of abuse (although fears of possible stimulant drug dependence in ADHD individuals appear to be largely groundless). The atypical stimulant modafinil has been considered in this context, as it is not thought to have drug abuse liability but retains many of the cognitive benefits of drugs such as methylphenidate. Its neurochemical action is complex; whilst it acts as a weak blocker of catecholamine transporters, it has several other actions that distinguish it from typical stimulant drugs, including possible indirect actions on glutamate and acetylcholine. However, modafinil has not been licensed to date for ADHD as it is not thought to be as clinically effective as the classical stimulants for example, in executive function and memory, which are a barrier to effective rehabilitation even if the psychotic symptoms are controlled. This is a little surprising as it can perhaps be argued that virtually the entire expression of schizophrenia, including the positive symptoms such as delusions and hallucinations, can be thought of as cognitive in nature, albeit in the case of negative symptoms such as an interaction between motivational and cognitive mechanisms. Only the positive symptoms are effectively treated, with both typical, “first-generation” antipsychotics which block DA D2 receptors (-R) and atypical (“second-generation”) antipsychotics which additionally block 5-HT2A-R, am ongst others. The psychological mechanisms of these antipsychotic effects are largely unknown but may work again to affect information processing in the striatum and neocortex. There is clearly a potential indirect benefit to be had on general cognitive processing if the disruptive positive symptoms are blunted, but it is in fact controversial whether there is any residual cognitive benefit, indirect or direct. Indeed, there is evidence from studies, both of nonhuman primates and humans, that chronic treatment with so-called “first-generation” antipsychotics acting as D2-R antagonists may eventually impair normal cognition.

The CATIE trial failed to find any advantage of the “second-generation” agents such as risperidone, quetiapine, and olanzapine compared with a typical antipsychotic agent perphenazine, although most of the drugs produced some small but significant improvements in a composite cognitive measure. The recent study by Veselinovic et al showed similar effect sizes, demonstrating the psychological mechanisms of these improvements (over baseline and when compared with placebo), with so-called “first-generation” antipsychotics acting as D2-R antagonists may eventually impair normative cognition.

Schizophrenia

It has only been relatively recently accepted that schizophrenia can be associated with profound cognitive deficits, for example, in executive function and memory, which are a barrier to effective rehabilitation even if the psychotic symptoms are controlled. This is a little surprising as it can perhaps be argued that virtually the entire expression of schizophrenia, including the positive symptoms such as delusions and hallucinations, can be thought of as cognitive in nature, albeit in the case of negative symptoms such as an interaction between motivational and cognitive mechanisms. Only the positive symptoms are effectively treated, with both typical, “first-generation” antipsychotics which block DA D2 receptors (-R) and atypical (“second-generation”) antipsychotics which additionally block 5-HT2A-R, amongst others. The psychological mechanisms of these antipsychotic effects are largely unknown but may work again to affect information processing in the striatum and neocortex. There is clearly a potential indirect benefit to be had on general cognitive processing if the disruptive positive symptoms are blunted, but it is in fact controversial whether there is any residual cognitive benefit, indirect or direct. Indeed, there is evidence from studies, both of nonhuman primates and humans, that chronic treatment with so-called “first-generation” antipsychotics acting as D2-R antagonists may eventually impair normative cognition.

The CATIE trial failed to find any advantage of the “second-generation” agents such as risperidone, quetiapine, and olanzapine compared with a typical antipsychotic agent perphenazine, although most of the drugs produced some small but significant improvements in a composite cognitive measure. The recent study by Veselinovic et al showed similar effect sizes, demonstrating the psychological mechanisms of these improvements (over baseline and when compared with placebo), with so-called “first-generation” antipsychotics acting as D2-R antagonists may eventually impair normative cognition.

It has only been relatively recently accepted that schizophrenia can be associated with profound cognitive deficits, for example, in executive function and memory, which are a barrier to effective rehabilitation even if the psychotic symptoms are controlled. This is a little surprising as it can perhaps be argued that virtually the entire expression of schizophrenia, including the positive symptoms such as delusions and hallucinations, can be thought of as cognitive in nature, albeit in the case of negative symptoms such as an interaction between motivational and cognitive mechanisms. Only the positive symptoms are effectively treated, with both typical, “first-generation” antipsychotics which block DA D2 receptors (-R) and atypical (“second-generation”) antipsychotics which additionally block 5-HT2A-R, amongst others. The psychological mechanisms of these antipsychotic effects are largely unknown but may work again to affect information processing in the striatum and neocortex. There is clearly a potential indirect benefit to be had on general cognitive processing if the disruptive positive symptoms are blunted, but it is in fact controversial whether there is any residual cognitive benefit, indirect or direct. Indeed, there is evidence from studies, both of nonhuman primates and humans, that chronic treatment with so-called “first-generation” antipsychotics acting as D2-R antagonists may eventually impair normative cognition.

The CATIE trial failed to find any advantage of the “second-generation” agents such as risperidone, quetiapine, and olanzapine compared with a typical antipsychotic agent perphenazine, although most of the drugs produced some small but significant improvements in a composite cognitive measure. The recent study by Veselinovic et al showed similar effect sizes, demonstrating the psychological mechanisms of these improvements (over baseline and when compared with placebo), with so-called “first-generation” antipsychotics acting as D2-R antagonists may eventually impair normative cognition.
Medications specifically targeting cognitive deficits and usually added to antipsychotic treatments have not been very effective on the whole. A recent meta-analysis by Sinkeviciute et al35 of 93 trials involving 5630 patients categorized cognitive enhancing effects in terms of the principal neurotransmitter affected. The most effective treatments were glutamergic, especially a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-R) agonists for working memory, which had a small positive effect. Agents acting at the glycine site of the NMDA receptor such as D-cycloserine and the glutamate receptor antagonist memantine showed some signs of improvement that were not significant, perhaps as a consequence of insufficient statistical power. The precise mechanism by which memantine achieves its effects is unclear. It may appear paradoxical that drugs acting as glutamate receptor agonists or antagonists may both have utility in the treatment of schizophrenia. However, NMDA receptor antagonists can enhance glutamate release in the cortex and some glutamatergic glutamate receptor agonists such as the mGluR2/3-R agonist pomaglutemad may normalize high levels of glutamate release via their actions at presynaptic receptors.56 This action is potentially significant as, following a meta-analysis of several clinical trials, this drug was shown to ameliorate positive symptoms in schizophrenia only within 3 years of the first psychotic episode.35 This may be consistent with theories that in the early phases of schizophrenia there is heightened activity of cortical pyramidal glutamatergic neurons, which may subsequently subside.29 Pomaglutemad has not yet been tested for its cognitive enhancing effects in schizophrenia, but this finding would suggest that any possible cognitive enhancing effects would be limited to first-episode patients.

The possible utility of glutamatergic compounds is interesting in view of some evidence that “nootropic” cognitive enhancing compounds such as aniracetam have been shown to have possible positive allosteric modulating activity at AMPA-R (ie, act as “AMPA-kines”).38 Early signs of promise of this class of drug in the treatment of mild dementia39 have not led to its wholesale use for Alzheimer disease. However, there is some recent evidence that aniracetam in terms of bioavailability and pharmacokinetic factors will be worth trying in schizophrenia as an adjunctive treatment to antipsychotic medication.40 Perhaps novel nootropic agents which overcome some of the problems associated with aniracetam in terms of bioavailability and pharmacokinetic factors will be worth trying in schizophrenia as an adjunctive treatment to antipsychotic medication.

Cholinergic strategies for schizophrenia run somewhat parallel to those used in the treatment of Alzheimer disease and dementia in Parkinson disease which appear to work mainly on attentional function.42,43 Cholinergic strategies for schizophrenia have utilized cholinesterase inhibitors such as donepezil and alpha7 nicotinic receptor agonists, with findings of very small positive effects in both cases. For example, Haig et al44 found a small improvement in nonsmoking patients with schizophrenia in verbal learning, working memory, and attention. On the other hand, a follow-up study by the same group did not confirm these findings.45 Sinkeviciute et al35 found no evidence for efficacy of agents affecting serotonergic, noradrenergic, and γ-amino butyric acid (GABA)-ergic receptors. However, they pointed out a glaring gap in the use of dopaminergic agents. This may appear to be surprising in view of the therapeutic use of DA D2-R antagonists, but there is substantial preclinical evidence that D1-R agonists may enhance working memory function in the primate prefrontal cortex46 as well as attention in rodent studies,44 which has never been adequately tested clinically. This has been due to existing compounds having poor brain penetration, short half-lives, and also some adverse cardiovascular effects. However, the advent of a new class of D1-R agonists with positive allosteric modulation (PAM) may be worth pursuing in an appropriate clinical trial.

In the current absence of a clinically viable D1-R agonist, other less specific agents, such as those used for ADHD, may also be worth further scrutiny. A considerable compound, pimozide, is the possible induction of psychosis by psychomotor stimulants such as amphetamine. However, it is possible that dopamine agents such as methylphenidate or modafinil may have some efficacy if investigated in large-scale trials in suitable groups of patients. In support of this hypothesis, Daniel et al46 found in an IMRI study of a small sample of patients with schizophrenia that d-amphetamine enhanced blood flow in the dorsolateral prefrontal cortex.
Pharmacological remediation of cognitive deficits - Robbins

...eral prefrontal cortex and improved performance on the Wisconsin Card Sorting Test. Likewise, Barch and Carter found benefit in several aspects of cognition including spatial working memory, language production, Stroop performance, and reaction time in 10 patients receiving d-amphetamine in addition to haloperidol medication. The rationale is that the D1-R action will be unaffected by the antipsychotic D2-R medication which may also block the psychotic effects of the drug. Turner et al showed that modafinil, which has mild catecholaminergic and possible glutamate-enhancing function, also improved performance in high functioning, first episode patients performing CANTAB tests of fronto-executive function including attentional-set shifting, recognition memory, planning, and response inhibition. However, longer-term treatment with either modafinil (or armodafinil) has so far failed to show significant effects. Nevertheless, a recent study found that the cognitive enhancing effects of acute modafinil in schizophrenia depended on some extent on the sensitivity of the cognitive test battery used, the CANTAB tests being more sensitive than the MATRICS battery. In general, factors such as this, as well as optimal dosing and the choice of suitable subgroups of patients with schizophrenia, given its heterogeneity, may be necessary to adequately test the efficacy of cognitive enhancers in schizophrenia.

Depression

Some of the major symptoms of depression such as impaired concentration and decision-making have an obvious cognitive nature. Indeed, cognitive dysfunction in depression has attracted considerable controversy because of the obvious interpretative problem, also relevant in terms of the “negative” symptom profile of schizophrenia, of motivational or mood factors in depression that may indirectly influence cognition. It has also been suggested that some of the cognitive difficulties in depression may have resulted from disruptive effects of enhanced responses to negative feedback. This motivational–cognitive interaction may thus be particularly important in depression. Nevertheless, it is now generally accepted that there are neurocognitive impairments in depression that are associated with poorer functional outcome and increased probability of relapse—and which imply a need to fully elucidate by current treatments for depression such as antidepressant medications. A recent meta-analysis showed a modest positive effect on functions such as divided attention, executive function, memory, and processing speed, recent and sustained attention (though not working memory) for depressed patients. However, this effect was largely limited to the selective serotonin reuptake inhibitors (SSRIs) rather than tricyclic antidepressants (perhaps because of their additional anticholinergic actions). The precise mechanisms underlying these cognitive enhancing effects of SSRIs is unknown. Chronic SSRIs, in addition to producing adaptive changes in serotonergic function may also affect other neurotransmitter systems (e.g., DA), and affect neurogenesis in the hippocampus. Prado et al do not rule out the possibility that the effects are indirect effects of mood enhancement. This relative lack of efficacy means that impairments are often still evident in remitted depressed patients. Hence cognition has recently become an important target for treatment in depression.

With this aim in view, McIntyre et al have reported cognitive enhancing actions in depression of 8 weeks of treatment with a novel SSRI antidepressant, vortioxetine on a composite cognition endpoint in a phase 1 dose-ranging study. Vortioxetine is an SSRI with additional actions at 5-HT3, and 5-HT7 receptors but it is not yet clear whether and how these contribute to cognitive enhancing effects. One suggestion has been that its 5-HT3 action may serve to disinhibit GABA-ergic receptors on interneurons. Further studies are indicated in healthy volunteers and in studies with experimental animals.

It may also be feasible to augment treatment of depression with SSRIs by other drugs that have greater cognitive enhancing efficacy. Goss et al found another meta-analysis that modafinil provided added benefit for cognition when combined with standard antidepressant medication. Kaser et al showed that modafinil did indeed act to improve working memory and episodic memory, but not planning or attention in remitted depressed patients.
Conclusions

There are indications of gradual progress in understanding and treating cognitive deficits in psychiatric disorders, but it is clear that there is much to be accomplished, in terms not only of identifying valid targets but also in the methods for assessing their effects in clinical trials and in experimental animal studies. A likely area of advance is in methods of evaluating social cognition and related form s, where emotional processing interacts with cognition (so-called “hot” cognition). For example, do any psychiatric disorders such as autism exhibit impairments in social cognition that are core to the disorder and may require novel neurobiological initiatives and methodological approaches, in addition to clinical trials. Attemptts to reme date social cognition in autism via intranasal oxytocin represents one such promising direction. Overall, this review has argued that more studies are required to define the mechanisms of cognitive enhancement produced by both currently employed and yet-to-be discovered pharmacological agents.

Disclosure/Acknowledgements: TWR consults for Cam bridge Cognition, Unilever, and Greenfields Bioventures Inc. He has held recent research grants from Shionogi, Lundbeck, and Smiths. He has royalty payments from CANTAB from Cambridge Cognition and editorial honoraria from Springer Nature and Elsevier.

References

1. Rhodes SM, Coghill DR, Matthews K. Methylphenidate restores visual attentional function in attention-deficit/hyperactivity disorder. Psychopharmacol. 2004;175:319-330.
2. Pirioti VA, Lai M-C, Muller U, et al. Neuroanatomical abnormal abilites and cognitive impairments in ADHD patients are shared by adults with attention deficit/hyperactivity disorder and their unaffected first-degree relatives. Biol Psychiatry. 2014;76:639-647.
3. Faroone SV. Using a meta-analysis to compare the efficacy of methylphenidate with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry. 2003;44:785-804.
4. Ebnis J, Welsh PA, Gulotta CS, Raps sow. J.L. Classroom academic performance: an improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry. 1993;34:785-804.
5. Ebnis J, Welsh PA, Gulotta CS, Raps sow. J.L. Classroom academic performance: an improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry. 1993;34:785-804.
6. S. Arnold LE, Hodgkins P, Kahle J, Madhoo M, Kewley G. Long-term outcome of ADHD: a clinical and performance. J Attention Dis. 2015;19:1-13.
7. Nakao T, Radua J, Rubia K, Mataix-Cols D. Gray matter after volume of abnormalities in ADHD: voxel based mta-ana-sis exploring the effects of age and stimulant medication. Am J Psychiatry. 2011;168:1154-1165.
8. Chamblerin SR, Robbins TW, Windler-Rhodes S, et al. Translational approaches to frontostriatal dysfunction in attention deficit/hyperactivity disorder using a computerized neuropsychological battery. Biol Psychiatry. 2011;69:1192-1203.
9. De Vito E, Blackwell AD, Kent L, et al. The effects of methylphenidate on decision-making in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;64:636-639.
10. Cools R, Barker R, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson’s disease as a function of dopaminergic medication and task demands. Cereb Cortex. 2001;11:136-1143.
11. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa enhancement of cognitive flexibility, but increases impulsivity in patients with Parkinson’s disease. Neuropharmacology. 2003;41:1431-1441.
12. Sprague RL, Sleator EK. Methylphenidate in hyperkinetic children: differences in the effects of learning and social behavior. Science. 1977;198:1274-1276.
13. Del Cam po N, Chamberlain SR, Sahakian BJ, Robbins TW. The roles of dopaminergic and noradrenergic influences on the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2011;69:e145-157.
14. Robbins TW, Arnsten AT. The neuropsychopharmacology of fronto-executive function: In one neuron in the m杏al. J. Ann Rev Neurosci. 2009;26:267-287.
15. Bari A, Mar AC, Theobald DEH, et al. Pre- and post-synaptic enhancement of top-signal performance in rats. J Neurosci. 2011;31:9254-9263.
16. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;62:977-984.
17. Aston-Jones G, Chiang C, Alexinsky, T. Discharge of noradrenergic locus coeruleus neurons in behaving rats and moneky suggests a role in vigilance. Prog Brain Res. 1991;88:501-520.
18. Lapiz MD, Morikita A. Noradrenergic modulation of cognitive function in rats diol prefrontal cortex as measured by attentional set shifting. Neurosci. 2006;137:1039-1049.
19. Goldm an-Rakivs PC. Cellular basis of working memory. Nature. 1995;14:477-485.
20. Gronan S, Pasotti F, Thom as KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci. 2005;20:1208-1215.
21. del Campo N, Fryer TD, Hong YT, et al. A positron emission tomography study of nigrostriatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain. 2013;136:3252-3270.
22. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of olfactory in healthy volunteers. Psychopharmacol. 2003;165:260-269.
23. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognitive performance in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55:1031-1040.
Original article
Pharmacological remediation of cognitive deficits - Robbins

28. Minzenberg MR, Canmor CS. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacol. 2008;33: 1477-1502.

29. Squeri I, Jones PB, Sahakian BJ. Modafinil effects on cognition and em o tion in schizophrenia and its neurochemical modulation in the brain. Neuropsychopharmacol. 2013;64:168-184.

30. Castner S, Williams GV, Goldm an-Rakic PS. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Sci ence. 2000;287:2020-2022.

31. Husa A, Moilanen J, Murray GK et al. Lifet ime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 2017;247:130-138.

32. Vesel inovic T, Scharpenberg M, Heinze M et al. Disparate effects of first and second generation antipsychotics on cognition in schizophrenia – Findings from the randomised NeSSy trial. Eur J Neuropsychopharmacol. 2019;29:720-739.

33. Keefe RS, Bilder RM, Davis SM et al. The cognitive effects of antipsychotic medications in schizophrenia: Results from the randomized NeSSy trial. Neuropsychopharmacol. 2017;42:19-23.

34. Lawrence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheimer’s disease: focus on cholinergic system. Nature. 1998;2:787-794.

35. Sinkeviciute I, Begarn am M, Prikken M et al. Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis. Schizophr Bull. 2018;44:22. doi:10.1093/schbul/sby112.

36. Moghadam B, Javitt D. From evolution to revolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacol. 2013;37:14-15.

37. Kinon BJ, Milen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the glutamate subtype 1 agonist pomaglat etal in schizophrenia. Biol Psychiatry. 2015;78: 754-762.

38. Suppiramaniyan V, Bahr BA, Sinnarajah S et al. Mem bran e of the Am pkine class of m e mo ry enhancers and its neurochemical modulation in the brain. Neuropsychopharmacol. 2013;64:168-184.

39. Koliaki CC, Messin s C, Tsolaki M. Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment and piraetam in healthy volunteers. J Psychopharmacol. 1990;4:299-302.

40. Lawr ence AD, Sahakian BJ. The cognitive psychopharmacology of Alzheim er’s disease: focus on cholinergic system. Nature. 1998;2:787-794.

41. Em re M, Aarsland D, Albanese A et al. Rvastigmine for dem entia associated with Parkin son’s disease. N Engl J Med. 2004;351:2590-2598.

42. Haig GM, Bain EE, Robison WZ et al. A randomised trial to assess the efficacy and safety of ABT-126, a selective a7 nicotinic acetylcholine receptor agonist, in the treatment of cognitive impairment in schizophrenia. Am J Psychiatry. 2016;173:827-835.

43. Haig G, Wang D, Othm an A.A., Zhao J. The alpha7 nicotinic agonist ABT-126 in the treatment of cognitive impairment associated with schizophrenia in non-smoke rs: Results from a randomised controlled phase 2b study. Neuropsychopharmacol. 2016;41:2983-2902.

44. Daniel DG, Weinberger DR, Jones DW. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neur osci. 1991;17:1907-1917.

45. Barch DM, Carter CS. Amphetamine im prov es cognitive function in m edicated individuals with schizophrenia and in healthy volunteers. Schiz Res. 2005;77:43-58.

46. Turner DC, Clark L, Pom ar-Clotet E et al. Modaf in ilim prov es cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacol. 2004;29:1363-1373.

47. Essi J, Michaloglou PG, Lewis SW. Modafin il and cognitive enhancement in schizophrenia and healthy volunteers: the effects of test battery in a randomised controlled trial. Psychol Med. 2017;47:2358-2368.

48. Elliott R, Sahakian BJ, McKay AP et al. Neuro psychological impairment in unipolar depression: the influence of perceived failure on subsequent performance. Psychol Med. 1996;26:975-989.

49. Prado CE, Watt S, C rove SF. A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed sames. Neuropsychol Res. 2018;28:32-72.

50. McIntyre RS, Lophaven S, Olsen CK. A randomised, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17:1557-1567.

51. Sanchez C, Asin KE, Artigas F. Vortioxetine, a new antidepressant with m ultimodal activity: a review of preclinical and clinical data. Pharmacol Ther. 2015;145:43-57.

52. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CHY. Modafinil augments enton therapy in unipolar and bipolar depression: A systematic review and meta-analysis of randomised controlled trials. J Clin Psychiatry. 2013;74:1101-1107.

53. Kaser M, Deakin JB, Michael A et al. Modafin ilim prov es episodic m em ory and working m em ory cognition in patients with rem itted depression: A double-blind, randomised, placebo-controlled study. Biol Psychiatr Cogn Neurosci Neuroim aging. 2017;2:115-122.

54. Gustella AJ, Einfeld SL, Gray KM et al. Intranasal oxytocin im prov es em otion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010;67:692-694.